Reportlinker Adds Stem Cell Therapy for Cardiac Diseases

Jan 04, 2010, 09:04 ET from Reportlinker

NEW YORK, Jan. 4 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Stem Cell Therapy for Cardiac Diseases

http://www.reportlinker.com/p0170483/Stem-Cell-Therapy-for-Cardiac-Diseases.html

Summary

Stem Cell Therapy for Cardiac Diseases report features 38 R & D product profiles, 33 company profiles and investors information. This report emphasizes advantages and disadvantages of particular cell therapies for heart diseases, mostly for myocardial infarction and heart failure, characteristics and origin of used cells, mechanism of their action, efficacy and adverse effects, and design of clinical trials.

It appears that the last eight years of prohibition of financing of embryonic stem cells research by the US government, and consequently their use for stem cell-based therapies, had significant negative impact on research and development in this field in the USA. Presently, embryonic stem cells are represented with only 8% among all R & D stem cell-based products undergoing development for the treatment of cardiac diseases. Out of four companies that are conducting development of embryonic stem cell-based therapies for cardiac diseases only two are from the USA. Mesenchymal stem cells (MSCs) obtained from bone marrow hold the dominant place between stem cell therapies undergoing development for cardiac diseases with 45%, followed by peripheral muscle stem cells (13%) and myocardial stem cells (10%). Human embryonic stem cells (hESCs) are used only in 8% of all products (Table 3). Out of 17 R & D products using mesenchymal stem cells 47% are products with undifferentiated MSCs.

The author's analysis reveals that unexpectedly high percentage (58%) of all stem cell-based R & D products for the treatment of cardiac diseases is in clinical stage of development, with half of them in advanced clinical stage. In the next 16 months, between December 2009 and April 2012, eight R & D products will complete Phase II and Phase III clinical trials and the value of stem cell-based therapy for cardiac diseases will be much more clear than today.

The author expects that the use of autologous mesenchymal stem cell-derived and human embryonic stem cell-derived cardiomyocytes and endothelial cells represent future trend in development of stem cell-based therapy for cardiac diseases.

Content:

1. Introduction

1.1. The Scope of the Problem of Cardiovascular Diseases

1.2. Stem Cell Therapy for Cardiac Diseases.

2. Stem Cells

2.1. Adult Stem Cells

2.1.1. Origin of Adult Stem Cells

2.1.2. Sources of Adult Stem Cells Used for the Treatment of Cardiac Diseases

2.1.3. Generation of Cardiomyocytes and Endothelial Cells from Adult Stem Cells

2.1.4. Types of Adult Stem Cells

2.1.4.1. Mesenchymal Stem Cells (MSCs)

2.1.4.2. Mesenchymal Stem-Like Stem Cells

2.1.5. Advantages and Disadvantages of Adult Stem Cells for Therapeutic Use in Cardiac Diseases

2.1.6. Types of Adult Stem Cell Transplantations for Cardiac Diseases

2.1.7. Manipulation of Adult Stem Cells Ex Vivo

2.1.7.1. Isolation of Adult Stem Cells

2.1.7.2. Expansion of Adult Stem Cells in Vitro (Bioreactors)

2.1.7.3. Adult Stem Cell Differentiation in Vitro (Biochips)

2.1.7.4. Encapsulation of Adult Stem Cells

2.1.7.5. Cryopreservation of Adult Stem Cells

2.1.8. Manipulation of Adult Stem Cells in Vivo

2.1.8.1. Activation of Dormant Adult Stem Cells in Vivo

2.1.8.2. Stimulation of Proliferation and Differentiation of Adult Stem Cells in Vivo

2.1.8.3. Mobilization of Adult Stem Cells in Vivo

2.2. Embryonic Stem Cells

2.2.1. Advantages and Disadvantages of Embryonic Stem Cells for Therapeutic Use

2.2.2. Growth of Embryonic Stem Cells

2.2.3. Differentiation of Embryonic Stem Cells

3. Pipeline Analysis

3.1. Types of Stem Cell Transplantations for Cardiac Diseases

3.2. Types and Sources of Stem Cells Utilized for the Treatment of Cardiac Diseases

3.3. Indications and Stages of Development

3.4. Expectations

4. R & D Product Profiles

5. Company Profiles

5.1. Other Cited Companies

6. Venture Capital Investors

7. Conclusion

A. Photos

Photo 1. EndGenitor's ECFCs® differentiating to form tube-like capillaries when stimulated in vitro

B. Tables

Table 1. Adult Stem Cells-Derived Cardiomyocytes and Endothelial Cells

Table 2. Stem Cell Therapies for Cardiac Diseases

Table 3. Type and Sources of Stem Cells Used for the Treatment of Cardiac Diseases

Table 4. Clinical Trials Schedule

Table 5. Companies and Investors

To order this report:

Cardiovascular Devices Industry: Stem Cell Therapy for Cardiac Diseases

More Market Research Report


    Contact:
    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com